Liraglutide
Also known as: Victoza · Saxenda
A daily GLP-1 receptor agonist FDA-approved for diabetes (Victoza) and obesity (Saxenda). Favored when rapid dosage titration is needed.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~13 hours
1.2–3.0 mg daily
Subcutaneous injection
Mechanism of Action
Augments incretin signaling to suppress appetite, slow gastric emptying, and enhance insulin sensitivity with rapid clearance for dose flexibility.
Key Research Areas
Frequently Asked Questions
What is Liraglutide?▾
How does Liraglutide work?▾
What is the recommended dosage for Liraglutide?▾
What is the half-life of Liraglutide?▾
Is Liraglutide FDA approved?▾
Research Disclaimer
The information provided about Liraglutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.